Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 413

Sort by

Sort Order Select

Journal Articles

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

Blood (2025) 146 (26): 3153–3162.

https://doi.org/10.1182/blood.2025028550

Published: 2025

Includes: Supplemental data

Journal Articles

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Blood (2025) 146 (20): 2406–2416.

https://doi.org/10.1182/blood.2025028899

Published: 2025

Includes: Supplemental data

Journal Articles

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Blood (2025) 146 (Supplement 1): 245.

https://doi.org/10.1182/blood-2025-245

Published: 2025

Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Blood (2025) 146 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2025-2137

Published: 2025

Journal Articles

Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies

Blood (2025) 146 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2025-2107

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Constantine Tam, Chan Cheah, John Seymour, Ricardo Parrondo, Mazyar Shadman, Damien Roos Weil, Stephan Stilgenbauer, Barbara Eichhorst, Herbert Eradat, Steven Treon, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Motohisa Takai, Amit Agarwal, Annamaria Frustaci

Blood (2025) 146 (Supplement 1): 3583.

https://doi.org/10.1182/blood-2025-3583

Published: 2025

Journal Articles

Impact of PRF 1 A91V germline carrier status in patients with aggressive b-NHL treated with rituximab

Blood (2025) 146 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2025-1750

Published: 2025

Journal Articles

Peptide-based antagonists for targeting CXCR4 in ibrutinib resistant chronic lymphocytic leukemia

Hannah Lea Wirth, Rashmi Priyadharshini Dheenadayalan, Dan Albers, Sofya Novikova, Andrea Gilg, Marcel Wieczorek, Eugen Tausch, Frank Kirchhoff, Jan Münch, Mirja Harms, Stephan Stilgenbauer, Billy Jebaraj

Blood (2025) 146 (Supplement 1): 5658.

https://doi.org/10.1182/blood-2025-5658

Published: 2025

Journal Articles

Barriers to optimal care and educational opportunities for european physicians treating patients with relapsed/refractory (R/R) CLL

Ryan Topping, Alexandra Howson, Timothy Quill, Stephan Stilgenbauer

Blood (2025) 146 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2025-2875

Published: 2025

Journal Articles

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

Blood (2025) 146 (Supplement 1): 795.

https://doi.org/10.1182/blood-2025-795

Published: 2025

Journal Articles

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Blood (2025) 146 (Supplement 1): 90.

https://doi.org/10.1182/blood-2025-90

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Blood (2025) 146 (Supplement 1): 85.

https://doi.org/10.1182/blood-2025-85

Published: 2025

Journal Articles

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Meghan Thompson, Annamaria Frustaci, John Seymour, John Allan, Paolo Ghia, Olivier Dumas, Franck Morschhauser, Martin Dreyling, Stephan Stilgenbauer, Inhye Ahn, Romain Guieze, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, Carlo Visco

Blood (2025) 146 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2025-3895

Published: 2025

Journal Articles

MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg

Paula Cramer, Léa Mazot, Sandra Robrecht, Adam Giza, Anna Maria Fink, Julia Von Tresckow, Petra Langerbeins, Florian Simon, Moritz Fürstenau, Othman Al-Sawaf, Kirsten Fischer, Eugen Tausch, Ludwig Fischer von Weikersthal, Clemens-Martin Wendtner, Sebastian Böttcher, Matthias Ritgen, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (Supplement 1): 5668.

https://doi.org/10.1182/blood-2025-5668

Published: 2025

Journal Articles

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch Albareda, Emadoldin Feyzi, Paolo Ghia, Michael Gregor, Arnon Kater, Vesa Lindström, Mattias Mattsson, Carsten Niemann, Philipp Staber, Tamar Tadmor, Patrick Thornton, Clemens-Martin Wendtner, Ann Janssens, Thomas Noesslinger, Jan-Paul Bohn, Caspar da Cunha-Bang, Christian Poulsen, Juha Ranti, Thomas Illmer, Bjoern Schoettker, Sebastian Böttcher, Tobias Gaska, Elisabeth Vandenberghe, Ruth Clifford, Ohad Benjamini, Annamaria Frustaci, Lydia Scarfo, Paolo Sportoletti, John Schreurs, Mark-David Levin, Hanneke van der Straaten, Marjolein van der Klift, Hoa Tran, Javier de la Serna, Javier Loscertales, Oscar Lindblad, Anna Bergendahl Sandstedt, Jeroen Goede, Michael Baumann, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Karl-Anton Kreuzer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (Supplement 1): 1.

https://doi.org/10.1182/blood-2025-1

Published: 2025

Journal Articles

Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project

Blood (2025) 146 (Supplement 1): 5299.

https://doi.org/10.1182/blood-2025-5299

Published: 2025

Journal Articles

A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL

Min Guo, Tugba Memis, Alena Sophie Ehrmann, Anselm Pittrof, Bernd Baumann, Francesca Ferrante, Eugen Tausch, Kirsten Fischer, Hartmut Döhner, Tilman Borggrefe, Stephan Stilgenbauer, Ulrich Pannicke, Klaus Schwarz, Daniel Mertens, Franz Oswald

Blood (2025) 146 (16): 1936–1949.

https://doi.org/10.1182/blood.2025028529

Published: 2025

Includes: Supplemental data

Journal Articles

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood (2025) 146 (3): 291–303.

https://doi.org/10.1182/blood.2024028064

Published: 2025

Includes: Supplemental data

Journal Articles

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Blood (2025) 145 (12): 1282–1292.

https://doi.org/10.1182/blood.2024026685

Published: 2025

Includes: Supplemental data

Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2024-203673

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Impact of PRF 1 A91V germline carrier status in patients with aggressive b-NHL treated with rituximab

Peptide-based antagonists for targeting CXCR4 in ibrutinib resistant chronic lymphocytic leukemia

Barriers to optimal care and educational opportunities for european physicians treating patients with relapsed/refractory (R/R) CLL

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project

A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only